Factors for progression and glaucoma treatment: The Early Manifest Glaucoma Trial

Current Opinion in Ophthalmology

Volumn 15, Issue 2, 2004, Pages 102-106

  Leske, M Cristina ^a   Heijl, Anders ^b   Hyman, Leslie ^a   Bengtsson, Bo ^b   Komaroff, Eugene ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Clinical trials; Glaucoma progression; Glaucoma treatment

Indexed keywords

BETAXOLOL;

ADULT; AGE; AGED; ARGON LASER; BLEEDING; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; EXFOLIATION SYNDROME; FEMALE; FOLLOW UP; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; OPTIC DISK; PERIMETRY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; REVIEW; RISK; TRABECULOPLASTY;

ANTIHYPERTENSIVE AGENTS; BETAXOLOL; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; LASER SURGERY; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; TRABECULECTOMY;

EID: 1842451860     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/00055735-200404000-00008     Document Type: Review

References (19)

1. Leske MC, Heijl A, Hyman L, et al.: Early manifest glaucoma trial. Design and baseline data. Ophthalmology 1999, 106:2144-2153.
2. Heijl A, Leske MC, Bengtsson B, et al.: Reduction of intraocular pressure and glaucoma progression - Results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002, 120:1268-1279. This paper is the first report of the results of the trial. It provides detailed information and comparisons of progression in treated and control patients, as well as on the intraocular pressure reduction achieved in the study.
3. Leske MC, Heijl A, Hussein M, et al.: Factors for glaucoma progression and the effect of treatment. Arch Ophthalmol 2003, 121:48-56. This paper provides additional results on the trial. It is the basis for the results on factors related to glaucoma progression, as presented in the current review.
4. Heijl A, Leske MC, Bengtsson B, et al.: Measuring visual field progression in the Early Manifest Glaucoma Trial. Acta Ophthalmol Scand 2003, 81:286-293. This paper concerns the main outcome measure used in the trial to denote glaucomatous visual field progression, which is expressed in terms of perimetric mean deviation and highly significant test points.
5. Cox DR: Regression models and life-tables (with discussion). J R Statis Soc 1972, 34:187-220.
6. Breslow NE: Covariance analysis of censored survival data. Biometrics 1974, 30:89-100.
7. Fluorouracil Filtering Surgery Study Group: Fluorouracil Filtering Surgery Study one-year follow-up. Am J Ophthalmol 1989, 108:625-635.
8. Glaucoma Laser Trial Research Group: The Glaucoma Laser Trial (GLT): Results of argon laser trabeculoplasty versus topical medicines. Ophthalmology 1990, 97:1403-1413.
9. The AGIS Investigators: The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000, 130:429-440.
10. Lichter PR, Musch DC, Gillespie BW, et al.: Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001, 108:1943-1953.
11. Collaborative Normal-Tension Glaucoma Study Group: Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998, 126:487-497.
12. Collaborative Normal-Tension Glaucoma Study Group: The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 1998, 126:498-505.
13. Kass MA, Heuer DK, Higginbotham EJ, et al.: The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002, 120:701-713.
14. Gordon MO, Beiser JA, Brandt JD, et al.: The ocular hypertension treatment study. Baseline factors that predict the progression of primary open-angle glaucoma. Arch Ophthalmol 2002, 120:714-720.
15. Yuksel N, Karabas VL, Arslan A, et al.: Ocular hemodynamics in pseudoexfoliation syndrome and pseudoexfoliation glaucoma. Ophthalmology 2001, 108:1043-1049.
16. Drance S, Anderson DR, Schulzer M: Risk factors for progression of visual field abnormalities in normal-tension glaucoma. Am J Ophthalmol 2001, 131:699-708.
17. Tezel G, Siegmund KD, Trinkaus K, et al.: Clinical factors associated with progression of glaucomatous optic disc damage in treated patients. Arch Ophthalmol 2001, 119:813-818.
18. Bengtsson B, Holmin C, Krakau CE: Disc haemorrhage and glaucoma. Acta Ophthalmology 1981, 59:1-14.
19. Rasker MT, van den Enden A, Bakker D, et al.: Deterioration of visual fields in patients with glaucoma with and without optic disc hemorrhages. Arch Ophthalmol 1997, 115:1257-1262.